Skip to content

Find our latest news, stories and press releases

Delivering long-term value for our stakeholders

Explore career opportunities and more

Impacting health for humanity

  1. Home/
  2. Media Center/
  3. Press releases /
  4. Innovative Medicine

Innovative Medicine

Interleukin-6 Inhibitor Sirukumab (CNTO 136) Phase 2 Data Show Promise In The Treatment Of Active Rheumatoid Arthritis

Sirukumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis in Patients with Active Disease Despite Treatment with Methotrexate

New Four Year STELARA™* Data Show Consistent Safety Profile Over Time In Patients With Moderate To Severe Plaque Psoriasis

Results Presented from the STELARA™ Clinical Development Program Also Demonstrate Consistency of Response across Multiple Ethnic Populations

Veridex Launches CELLTRACKS® Circulating Melanoma Cell Kit For Research Use

Automated process gives researchers a simple, reliable method to capture and count circulating melanoma cells

FDA Approves EDURANT™ (rilpivirine) For Use in Treatment-Naïve Adults with HIV-1

Third medication for Tibotec Therapeutics HIV treatment portfolio

Phase 2b Data Show Treatment With STELARA® Induced and Maintained Clinical Response in Patients With Moderate to Severe Crohn’s Disease

Study Findings Show Efficacy of STELARA in Patients Who Previously Had Inadequate Response to Tumor Necrosis Factor Antagonists

New Phase 3 Study Results Show REMICADE® is Effective in the Treatment of Pediatric Patients With Moderate to Severe Ulcerative Colitis

Study Findings Demonstrate Clinical Response with REMICADE in Pediatric Patients Who Have Not Responded to Conventional Therapy